ERBB2 and carcinoma: Currently, NAC in breast cancer has been accepted as a standard therapeutic procedure for patients with different selection criteria such as: clinical lymph node involvement, tumor size > 2 cm, triple-negative breast cancer, HER2-positive breast cancer, high proliferation index carcinoma, unresectable breast cancer tumors and inflammatory breast carcinoma [35].